Myriad Genetics announces patent granted for SneakPeek Snap device

Myriad Genetics announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination.U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap products in the U.S through 2040. The patent further covers technology for improving the accuracy of a fetal sex test by reducing contaminating DNA in maternal blood samples. SneakPeek’s blood collection innovation makes obtaining a blood sample at home quick and easy. Consumers place the Snap device on their arm, press the button, and the sample is collected in one to four minutes. Moreover, clinical studies have shown that the Snap device significantly reduces the risk of external male DNA contamination in maternal blood samples, ensuring high accuracy in fetal sex testing. “We view this patent grant as recognition of our innovative approach to fetal sex testing using PCR-based techniques with any push-button blood collection device,” stated Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. “This patent grant promotes SneakPeek Snap exclusivity in the US market through at least 2040 and provides an opportunity for licensing agreements with leading push-button blood collection device suppliers, positioning us as a strategic partner.”